ArticleScientific reports2025
Burden of ischemic stroke attributable to high low-density lipoprotein cholesterol in China from the global burden of disease study 2021.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of Clinical Pharmacist-Led Medication Management on Medication Adherence and Quality of Life in Stroke Patients Undergoing Intravenous Thrombolysis.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
High low-density lipoprotein cholesterol are a significant risk factor for ischemic stroke. This study aims to analyze the burden of disease and temporal trends of ischemic stroke attributable to high LDL-C (IS-hLDL-C) in China, thereby providing a scientific basis for the development of effective prevention and intervention strategies. This study extracted the age-standardized mortality rates (ASMRs) and age-standardized disability-adjusted life years rates (ASDRs) of IS-hLDL-C from the global burden of disease (GBD) 2021. Stratified analysis was performed by gender and age groups. Joinpoint regression models were used to calculate average annual percentage changes (AAPC) to assess trends in IS-hLDL-C burden between 1990 and 2021. Age-period-cohort (APC) model to estimate the independent effects of age, period, and cohort on IS-hLDL-C burden. In 2021, the total number of IS-hLDL-C deaths in China was 300,052 (95% UI 92,515-527,456), and disability-adjusted life years (DALYs) was 6,850,565 (95% UI 2,313,203 - 11,418,167). From 1990 to 2021, ASMRs changed from 18.23 (95% CI 5.52-33.43) to 15.93 (95% CI 4.83-28.08), and the AAPC was -0.47 (95% CI -0.83 to -0.10). The ASDRs decreased from 385.65 (95% CI 129.83 to 647.51) in 1990 to 335.59 (95% CI 112.75 to 566.25) in 2021, with an AAPC of -0.49 (95% CI -0.83 to -0.10). Sex-stratified analysis showed that male had greater ASMRs and ASDRs than female. Age-stratified analysis showed that the burden was greatest among the elderly. In the age-period-cohort analysis, the age effect of IS-hLDL-C showed a continuous increasing trend during the study period. The period effect generally showed a positive trend during the study period. From 1990 to 2021, while the ASMRs and ASDRs related to IS-hLDL-C have decreased in China, the absolute numbers of deaths and DALYs remain substantial. The burden of IS-hLDL-C disease is disproportionately higher among male and the elderly. Given large population and the ongoing trend of population aging, it is essential to consider various lipid-lowering strategies in the future to allocate healthcare resources effectively and reduce the disease burden associated with IS-hLDL-C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.